Form 13-F position report

NAUTILUS BIOTECHNOLOGY INC

Reported by ArchPoint Investors

NAUT CUSIP 63909J108 Manager CIK 0001483472

Reported 606,133 shares, down 8,138 (1.3%) from the prior quarter.

Reported value -41.8%; share count -1.3% vs. the prior quarter.

Reduced
% of reported 13F value 0.33% This manager · Q4 2024
Shares 606,133 Quarter-end amount reported
Reported value $1,018,303 Fair value at quarter end
Consecutive quarters held 3 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 7509000
2022-03-31 6291000
2022-06-30 3899000
2022-09-30 3073000
2022-12-31 2609192
2023-03-31 4015256
2023-06-30 5609762
2023-09-30 4580581
2023-12-31 0
2024-06-30 1437394
2024-09-30 1750672
2024-12-31 1018303
2025-03-31 521881
2025-06-30 451184
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for NAUTILUS BIOTECHNOLOGY INC held by ArchPoint Investors.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -622,409 (-100.0%) 0 $0 2025-11-12
Q2 2025 Added 622,409 +16,276 (2.7%) 0.13% $451,184 2025-08-13
Q1 2025 Unchanged 606,133 0 (0.0%) 0.17% $521,881 2025-05-14
Q4 2024 Reduced 606,133 -8,138 (-1.3%) 0.33% $1,018,303 2025-02-13
Q3 2024 Unchanged 614,271 0 (0.0%) 0.58% $1,750,672 2024-11-13
Q2 2024 New 614,271 +614,271 (0.0%) 0.54% $1,437,394 2024-08-13
Q4 2023 Reduced 0 -1,449,551 (-100.0%) 0 $0 2024-02-13
Q3 2023 Unchanged 1,449,551 0 (0.0%) 1.75% $4,580,581 2023-11-13
Q2 2023 Unchanged 1,449,551 0 (0.0%) 2.17% $5,609,762 2023-08-11
Q1 2023 Unchanged 1,449,551 0 (0.0%) 1.75% $4,015,256 2023-05-12
Q4 2022 Unchanged 1,449,551 0 (0.0%) 1.24% $2,609,192 2023-02-13
Q3 2022 Unchanged 1,449,551 0 (0.0%) 1.25% $3,073,000 2022-11-14
Q2 2022 Unchanged 1,449,551 0 (0.0%) 1.55% $3,899,000 2022-08-12
Q1 2022 Unchanged 1,449,551 0 (0.0%) 2.17% $6,291,000 2022-05-13
Q4 2021 New 1,449,551 +1,449,551 (0.0%) 2.23% $7,509,000 2022-02-11

Who else reported the position

98 managers reported NAUTILUS BIOTECHNOLOGY INC for Q4 2024.

Managers reporting NAUTILUS BIOTECHNOLOGY INC in Q4 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
AH Capital Management L L C Unchanged 17,653,917 0 3.98% $29,658,581 5 qtrs
PERCEPTIVE ADVISORS LLC Unchanged 12,594,211 0 0.58% $21,158,274 15 qtrs
Cercano Management LLC Unchanged 7,172,985 0 0.31% $12,050,615 9 qtrs
Madrona Venture Group LLC Unchanged 6,020,770 0 18.8% $10,115,000 15 qtrs
BlackRock Inc Reduced 3,068,737 -496,506 < 0.01% $5,155,478 2 qtrs
VANGUARD GROUP INC Added 2,778,449 +12,106 < 0.01% $4,667,794 14 qtrs
Comprehensive Financial Management LLC Reduced 2,207,619 -1 0.1% $3,708,800 15 qtrs
Bain Capital Life Sciences Investors LLC Reduced 1,759,000 -241,000 0.35% $2,955,120 15 qtrs
AMAZON COM INC Unchanged 1,457,055 0 0.09% $2,447,852 15 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,142,542 +7,000 < 0.01% $1,919,736 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 13, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
606,133
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.